Phase 4Completed

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

Sponsor
Tufts Medical Center (Academic or other)
Enrollment
21 enrolled
Conditions
Cytomegalovirus Infections; Infection in Solid Organ Transplant Recipients; Neutropenia; Antiviral Toxicity
Interventions
Letermovir
Ages
adults, older adults
Registry
NCT05626530

Full record on ClinicalTrials.gov

From the registry

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.

Primary outcomes

  • Rate of Relapse after prophylaxis

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered